Procter & Gamble (PG)

The sleeper story is that P&G's 4.0% organic growth is less a share-gain story than a rising-tide-plus-one-time-windfall story: global aggregate market share is still flat, and management itself quantified roughly 3 points of China's acceleration as a competitor's trial windfall on Pampers, admitting that ex-that benefit China is 'still growing at the 5%'. The obvious headline, a beat-and-reaffirm quarter with EPS up 1% against a prior call for a 5%+ decline, is real, but the binding constraint going forward is commodity costs, not demand: the cost headwind jumped from $1.0B to $1.4B after-tax in a single quarter and Andre flagged spot oil 'north of 110' as a further unguided risk. The most revealing line on the call wasn't about China or costs, it was Andre's hedge on EPS positioning after a beat: 'I'm confident in the range, but we'll need time to figure out where that range will end up', a notable retreat from last quarter's specific '$7 at the center of the range'. My view changes if China's baby care growth holds above 20% for two more quarters after the competitor disruption fades, or if Q2 cost headwinds come in below the newly guided $1.9B combined figure, either would confirm this is durable share-taking rather than a cyclical and competitive sugar high.